Daphne W Bell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1107623/publications.pdf Version: 2024-02-01



DADHNE W RELL

#	Article	IF	CITATIONS
1	Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 2004, 350, 2129-2139.	13.9	10,632
2	Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics, 2005, 37, 1315-1316.	9.4	468
3	Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature, 2001, 413, 311-316.	13.7	411
4	Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nature Genetics, 2012, 44, 1310-1315.	9.4	365
5	Clinical actionability of molecular targets in endometrial cancer. Nature Reviews Cancer, 2019, 19, 510-521.	12.8	261
6	A Unique Spectrum of Somatic <i>PIK3CA</i> (p110α) Mutations Within Primary Endometrial Carcinomas. Clinical Cancer Research, 2011, 17, 1331-1340.	3.2	208
7	<i>PIK3R1</i> (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer. Cancer Research, 2011, 71, 4061-4067.	0.4	202
8	Molecular Genetics of Endometrial Carcinoma. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 339-367.	9.6	163
9	The genomics and genetics of endometrial cancer. Advances in Genomics and Genetics, 2012, 2012, 33.	0.8	96
10	The Emerging Genomic Landscape of Endometrial Cancer. Clinical Chemistry, 2014, 60, 98-110.	1.5	88
11	Our changing view of the genomic landscape of cancer. Journal of Pathology, 2010, 220, 231-243.	2.1	82
12	Genetic and functional analysis of <i>CHEK2</i> (<i>CHK2</i>) variants in multiethnic cohorts. International Journal of Cancer, 2007, 121, 2661-2667.	2.3	75
13	Predisposition to Cancer Caused by Genetic and Functional Defects of Mammalian Atad5. PLoS Genetics, 2011, 7, e1002245.	1.5	73
14	Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer, 2017, 123, 3261-3268.	2.0	72
15	Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences. Advances in Experimental Medicine and Biology, 2017, 943, 3-46.	0.8	64
16	Next-Generation Sequencing. Advances in Experimental Medicine and Biology, 2017, 943, 119-148.	0.8	54
17	Recurrent patterns of DNA methylation in the <i>ZNF154,CASP8</i> , and <i>VHL</i> promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines. Epigenetics, 2013, 8, 1355-1372.	1.3	52
18	The mutational landscape of endometrial cancer. Current Opinion in Genetics and Development, 2015, 30, 25-31.	1.5	35

DAPHNE W BELL

#	Article	IF	CITATIONS
19	Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development. Journal of Molecular Diagnostics, 2016, 18, 283-298.	1.2	33
20	The <i>FOXA2</i> transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer, 2018, 124, 65-73.	2.0	27
21	Sequencing of Candidate Chromosome Instability Genes in Endometrial Cancers Reveals Somatic Mutations in ESCO1, CHTF18, and MRE11A. PLoS ONE, 2013, 8, e63313.	1.1	27
22	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget, 2017, 8, 84579-84594.	0.8	23
23	Novel genetic targets in endometrial cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 725-730.	1.5	16
24	Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. BMC Cancer, 2014, 14, 884.	1.1	14
25	In vitro effects of <i>FBXW7</i> mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to Slâ€2 and dinaciclib. Molecular Carcinogenesis, 2018, 57, 1445-1457.	1.3	12
26	Proteomic profiling of FBXW7 â€mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target. Cancer Medicine, 2020, 9, 3863-3874.	1.3	7
27	Highâ€risk endometrial cancer proteomic profiling reveals that <i>FBXW7</i> mutation alters L1CAM and TGM2 protein levels. Cancer, 2021, 127, 2905-2915.	2.0	6
28	High-resolution copy number analysis of clear cell endometrial carcinoma. Cancer Genetics, 2020, 240, 5-14.	0.2	5
29	Reply to <i>FBXW7</i> , <i>L1CAM</i> , and <i>TGM2</i> in endometrial cancer. Cancer, 2021, 127, 4105-4105.	2.0	2
30	KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas. PLoS ONE, 2022, 17, e0251286.	1.1	2